The treatment landscape of mantle cell lymphoma (MCL) is continually evolving. In this podcast, an advanced practice provider and a medical oncologist discuss recent trials in MCL from the ASCO Annual Meeting 2022 and how this data may impact practice. Topics include the addition of a BTK inhibitor to chemotherapy in the first-line setting and novel compounds in development. Listeners can earn 0.50 credit hours. Download the supplemental PowerPoint slides below for additional education.


This activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

If you have already listened to the podcast, use the button below to access the post-test and evaluation and receive your certificate.


Tycel J. Phillips, MD Maria Reinhardt Decesare Research Professor of Blood Cancers and Bone Marrow Transplantation Associate Professor of Medicine University of Michigan Rogel Cancer Center Ann Arbor, Michigan

Amy Goodrich, MSN, NP-AC Research Associate Johns Hopkins University Nurse Practitioner Department of Medicine The Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland

Development Widget